If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Upcoming IPO
Priced IPO
Solaredge Technologies, Inc. (SEDG)
The Marygold Companies (MGLD)
Blue Water Vaccines (BWV)
Meihua International Medical Technologies (MHUA)
Smart for Life (SMFL)
Vivakor (VIVK)
TC BioPharm Holdings (TCBP)
Direct Digital Holdings, Llc (DRCT)
Modiv (MDV)
Sky Technologies (SKYX)
Modular Medical (MODD)
HeartCore Enterprises (HTCR)
Arcellx, Inc. (ACLX)
Silver Spike Investment Corp. (SSIC)
Maris-Tech Ltd. (MTEK)
Yoshitsu Co., Ltd. (TKLF)
Tpg Inc. (TPG)
Hillstream BioPharma (HILS)
Hour Loop (HOUR)
Vigil Neuroscience, Inc. (VIGL)
More companies

Jupiter Neurosciences, Inc. (JUNS)

IPO Profile

About company

(Note: This is a unit IPO consisting of 3.33 million units to be priced between $5 and $7 each.)Jupiter Neurosciences, Inc. is a clinical stage research and development pharmaceutical company that has developed a unique resveratrol platform product primarily targeting treatment of neuro-inflammation. The product candidate, called JOTROL™, has many potential indications of use for rare diseases, which they primarily are targeting Mucopolysaccharidoses Type 1, Friedreich’s Ataxia, and MELAS and with ALS in an earlier development stage. In the larger disease areas, they are primarily targeting Mild Cognitive Impairment/early Alzheimer’s disease with an early development program in TBI (traumatic brain injury)/concussions.In 2020, they received approval for full funding, $1.76 million, for their Phase I study from the National Institute on Aging (“NIA”). They plan to continue pursuing grant funding opportunities in all areas where they are available, such as Phase II and Phase III trials in Alzheimer’s disease as well as any funding available for their rare disease projects. In the NIA scientific review summary statement of their Phase I study application, it is stated that NIA is looking forward to a Phase II study with an enhanced resveratrol product, based on the earlier study results from the well published Turner et al. Alzheimer’s study. They recently submitted a grant application to NIA for full funding, including corporate overhead for a total of $18.3 million, for the duration of the study, of a Phase II trial in Mild Cognitive Impairment (MCI) and early Alzheimer’s disease. There is however no guarantee that this and future grant applications will be successful and therefore the rejection of their future grant application may significantly delay the Company’s plans in connection with MCI and Alzheimer’s and may have a significant impact on the Company’s financial performance. Further, the Company may never receive any future grants or costs savings.(Note: The pricing of Jupiter Neurosciences, Inc.’s IPO is tentatively expected late in the week of Jan. 17, 2022; the U.S. stock market will be closed on Monday for the Martin Luther King Jr. holiday.)
Pharmaceutical Preparations
Employees Founded
5 2016


Address: Jupiter Neurosciences, Inc. 1001 North Us Hwy 1, Suite 504 Jupiter, Florida 33477

Telephone: (561) 406-6154

Web page:

IPO information

Expected Date 2/11/2022
Status Upcoming
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Shares & Volumes

Shares Initial (MM) 3.3
Shares Revised (MM) -
Expected offer amount (MM) $20
Realized offer amount(MM) -

Financial Data (last reporting year)

Market Cap (MM) $61.18
Revenues (MM) $0
Net Income (Loss) (MM) $-2.75


What do you think will happen with the JUNS share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Roth Capital Partners

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Roth Capital Partners/ Dawson James Securities

Tweets about $JUNS

Tweets volume:

RT volume:


Google Trends Stats